BACKGROUND: The use of oral nutritional supplements (ONS) is common practice in patients suffering from cystic fibrosis (CF). We aimed to describe the rate of ONS use to assess their contribution to dietary intake and to determine if they are associated with respiratory status, body composition, muscle strength, bone mineral density (BMD), bone remodeling biomarkers, and plasmatic levels of vitamins. METHODS: Cross-sectional study. Patients were clinically stable adults recruited from the CF unit. A 4-day prospective dietary questionnaire was conducted; in addition to respiratory variables, body composition, and BMD (through densitometry, DXA), muscle strength (JAMAR dynamometer), fat-soluble vitamins, and bone remodeling biomarkers (vitamins A, D, and E; osteocalcin, OC; undercarboxylated osteocalcin, ucOC; degradation of the C-terminal telopeptides of type I collagen, CTX; and receptor activator of nuclear factor-kappaB ligand, RANKL) were also evaluated. RESULTS: The study included 59 subjects with CF (57.6% female, mean age 29.3 ± 9.4 years, and BMI 22.0 ± 3.6 kg/m2). In this study, 22% (13) patients were taking ONS and presented, compared with those not taking them, significantly more total and mild exacerbations and lower BMI; moreover, they showed a significantly higher total daily calorie intake in addition to a higher consumption of carbohydrates, proteins, and lipids per kg of body weight, omega-3 fatty acids, and vitamins A, D, and E. Vitamin E plasmatic levels were significantly higher in the group on ONS, as was the case with RANKL; finally, a lower rate of vitamin D deficiency was also found. CONCLUSIONS: ONS were used by patients with worse respiratory and nutritional statuses and their use was associated with a higher intake of macro- and micronutrients and with better plasmatic levels of fat-soluble vitamins.
BACKGROUND: The use of oral nutritional supplements (ONS) is common practice in patients suffering from cystic fibrosis (CF). We aimed to describe the rate of ONS use to assess their contribution to dietary intake and to determine if they are associated with respiratory status, body composition, muscle strength, bone mineral density (BMD), bone remodeling biomarkers, and plasmatic levels of vitamins. METHODS: Cross-sectional study. Patients were clinically stable adults recruited from the CF unit. A 4-day prospective dietary questionnaire was conducted; in addition to respiratory variables, body composition, and BMD (through densitometry, DXA), muscle strength (JAMAR dynamometer), fat-soluble vitamins, and bone remodeling biomarkers (vitamins A, D, and E; osteocalcin, OC; undercarboxylated osteocalcin, ucOC; degradation of the C-terminal telopeptides of type I collagen, CTX; and receptor activator of nuclear factor-kappaB ligand, RANKL) were also evaluated. RESULTS: The study included 59 subjects with CF (57.6% female, mean age 29.3 ± 9.4 years, and BMI 22.0 ± 3.6 kg/m2). In this study, 22% (13) patients were taking ONS and presented, compared with those not taking them, significantly more total and mild exacerbations and lower BMI; moreover, they showed a significantly higher total daily calorie intake in addition to a higher consumption of carbohydrates, proteins, and lipids per kg of body weight, omega-3 fatty acids, and vitamins A, D, and E. Vitamin E plasmatic levels were significantly higher in the group on ONS, as was the case with RANKL; finally, a lower rate of vitamin D deficiency was also found. CONCLUSIONS:ONS were used by patients with worse respiratory and nutritional statuses and their use was associated with a higher intake of macro- and micronutrients and with better plasmatic levels of fat-soluble vitamins.
Authors: F Soriguer; S Serna; E Valverde; J Hernando; A Martín Reyes; M Soriguer; A Pareja; F Tinahones; I Esteva Journal: Nutr Hosp Date: 1996 Jul-Aug Impact factor: 1.057
Authors: Carlo Castellani; Alistair J A Duff; Scott C Bell; Harry G M Heijerman; Anne Munck; Felix Ratjen; Isabelle Sermet-Gaudelus; Kevin W Southern; Jurg Barben; Patrick A Flume; Pavla Hodková; Nataliya Kashirskaya; Maya N Kirszenbaum; Sue Madge; Helen Oxley; Barry Plant; Sarah Jane Schwarzenberg; Alan R Smyth; Giovanni Taccetti; Thomas O F Wagner; Susan P Wolfe; Pavel Drevinek Journal: J Cyst Fibros Date: 2018-03-03 Impact factor: 5.482
Authors: Steven P Conway; Susan P Wolfe; Keith G Brownlee; Helen White; Brian Oldroyd; John G Truscott; Julia M Harvey; Martin J Shearer Journal: Pediatrics Date: 2005-05 Impact factor: 7.124
Authors: Francisco José Sánchez Torralvo; Nuria Porras; José Abuín Fernández; Francisca García Torres; María José Tapia; Fuensanta Lima; Federico Soriguer; Montserrat Gonzalo; Gemma Rojo Martínez; Gabriel Olveira Journal: Nutr Hosp Date: 2018-01-16 Impact factor: 1.057
Authors: T Cederholm; I Bosaeus; R Barazzoni; J Bauer; A Van Gossum; S Klek; M Muscaritoli; I Nyulasi; J Ockenga; S M Schneider; M A E de van der Schueren; P Singer Journal: Clin Nutr Date: 2015-03-09 Impact factor: 7.324
Authors: Kara L Murray; Carlton K K Lee; Peter J Mogayzel; Pamela L Zeitlin; Beryl J Rosenstein Journal: Am J Health Syst Pharm Date: 2008-03-15 Impact factor: 2.637